A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran
The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Summary: Idarucizumab, a monoclonal antibody fragment that binds dabigatran with high affinity, is in development as a specific antidote for dabigatran. In this first-in-human, single-rising-dose study, we investigated the pharmacokinetics, safety and tolerability of idarucizumab. Healthy male volunteers aged 18–45 years received between 20 mg and 8 g idarucizumab as a 1-hour intravenous infusion in 10 sequential dose groups, or 1, 2 or 4 g idarucizumab as a 5-minute infusion. Subjects within each dose group were randomised 3:1 to idarucizumab or placebo. A total of 110 randomised subjects received study drug (27 placebo, 83 idarucizumab). Peak and total exposure to idarucizumab increased proportionally with dose. Maximum plasma concentrations were achieved near the end of infusion, followed by a rapid decline, with an initial idarucizumab half-life of ∼45 minutes. For the 5-minute infusions, this resulted in a reduction of plasma concentrations to less than 5 % of peak within 4 hours. Idarucizumab (in the absence of dabigatran) had no effect on coagulation parameters or endogenous thrombin potential. Overall adverse event (AE) frequency was similar for idarucizumab and placebo, and no relationship with idarucizumab dose was observed. Drug-related AEs (primary endpoint) were rare (occurring in 2 placebo and 3 idarucizumab subjects) and were mostly of mild intensity; none of them resulted in study discontinuation. In conclusion, the pharmacokinetic profile of idarucizumab meets the requirement for rapid peak exposure and rapid elimination, with no effect on pharmacodynamic parameters. Idarucizumab was safe and well tolerated in healthy males. Clinical trial registration: http://clinicaltrials.gov/ct2/show/NCT01688830?term=NCT01688830&rank=1 (NCT01688830).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dabigatran versus warfarin in patients with atrial fibrillation
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905561 · Cited by 11,215 · cited 1×
“We calculated based on median peak concentrations of dabigatran seen in atrial fibrillation patients from the RE-LY study who received 150 mg dabigatran twice daily (1) that an equimolar ratio of idarucizumab to the total body load of 8 g, 1-h Infusion 4 g, 5-min Infusion”
MethodDabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
Schulman, S., Kearon, C., Kakkar, A. K., Mismetti, P., Schellong, S., Eriksson, H., Baanstra, D., Schnee, J., & Goldhaber, S. Z. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0906598 · Cited by 2,583
Stangier, J., Haertter, S., Liesenfeld, K.-H., Wienen, W., Feuring, M., Clemens, A., & Ryn, J. V. (2010) · Thrombosis and Haemostasis · doi:10.1160/th09-11-0758 · Cited by 1,382
Self-citationTreatment of Acute Venous Thromboembolism With Dabigatran or Warfarin and Pooled Analysis
Schulman, S., Kakkar, A. K., Goldhaber, S. Z., Schellong, S., Eriksson, H., Mismetti, P., Christiansen, A. V., Friedman, J., Le Maulf, F., Peter, N., et al. (2014) · Circulation · doi:10.1161/circulationaha.113.004450 · Cited by 923
Reilly, P. A., Lehr, T., Haertter, S., Connolly, S. J., Yusuf, S., Eikelboom, J. W., Ezekowitz, M. D., Nehmiz, G., Wang, S., & Wallentin, L. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.07.104 · Cited by 834 · cited 3×
“Patients with bleeding may also have elevated concentrations compared with patients without major bleeding (19).”
BackgroundSelf-citationNewly identified events in the RE-LY trial
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Reilly, P. A., & Wallentin, L. (2010) · New England Journal of Medicine · doi:10.1056/nejmc1007378 · Cited by 688
Self-citationStangier, J. (2008) · Clinical Pharmacokinetics · doi:10.2165/00003088-200847050-00001 · Cited by 655 · cited 1×
“109 M sodium citrate) collected by venipuncture using validated assays (13, 14).”
MethodSelf-citationA specific antidote for dabigatran: functional and structural characterization
Schiele, F., van Ryn, J., Canada, K., Newsome, C., Sepulveda, E., Park, J., Nar, H., & Litzenburger, T. (2013) · Blood · doi:10.1182/blood-2012-11-468207 · Cited by 563 · cited 11×
“In in vitro studies, idarucizumab showed no binding to known thrombin substrates, and no activity in coagulation or platelet aggregation tests (10, 11).”
BackgroundResultInfluentialHeidbuchel, H., Verhamme, P., Alings, M., Antz, M., Hacke, W., Oldgren, J., Sinnaeve, P., Camm, A. J., & Kirchhof, P. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht134 · Cited by 405
Endocytic Receptors in the Renal Proximal Tubule
Christensen, E. I., Birn, H., Storm, T., Weyer, K., & Nielsen, R. (2012) · Physiology · doi:10.1152/physiol.00022.2012 · Cited by 287 · cited 2×
“A dose-dependent, transient increase in urine protein and lowweight proteins, concurrent with the transient urinary excretion of idarucizumab, may indicate saturation of tubular uptake processes for the reabsorption of proteins from the filtrate (16).”
BackgroundResultManagement and Outcomes of Major Bleeding During Treatment With Dabigatran or Warfarin
Majeed, A., Hwang, H.-G., Connolly, S. J., Eikelboom, J. W., Ezekowitz, M. D., Wallentin, L., Brueckmann, M., Fraessdorf, M., Yusuf, S., & Schulman, S. (2013) · Circulation · doi:10.1161/circulationaha.113.002332 · Cited by 277 · cited 1×
“The overall bleeding profile (1–4) and the outcome of major bleeding (6) are favourable for dabigatran compared with warfarin.”
Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran
Stangier, J., & Feuring, M. (2012) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0b013e32834f1b0c · Cited by 265 · cited 1×
“109 M sodium citrate) collected by venipuncture using validated assays (13, 14).”
MethodSelf-citationBehr, T. M., Sharkey, R. M., Juweid, M. E., Blumenthal, R. D., Dunn, R. M., Griffiths, G. L., Bair, H. J., Wolf, F., Becker, W. S., & Goldenberg, D. M. (1995) · PubMed · Cited by 176
Characterizing the Impact of Renal Impairment on the Clinical Pharmacology of Biologics
Meibohm, B., & Zhou, H. (2012) · The Journal of Clinical Pharmacology · doi:10.1177/0091270011413894 · Cited by 146 · cited 1×
“As with most small proteins, a major fraction of idaru cizumab is expected to be eliminated by renal catabolism (15).”
BackgroundFriedman, R. J., Dahl, O. E., Rosencher, N., Caprini, J. A., Kurth, A. A., Francis, C. W., Clemens, A., Hantel, S., Schnee, J. M., & Eriksson, B. I. (2010) · Thrombosis Research · doi:10.1016/j.thromres.2010.03.021 · Cited by 144
Reduction of renal uptake of monoclonal antibody fragments by amino acid infusion.
Behr, T. M., Becker, W., Sharkey, R. M., et al. (1996) · PubMed · Cited by 82
Reversal of antithrombotic agents
Bauer, K. A. (2012) · American Journal of Hematology · doi:10.1002/ajh.23165 · Cited by 80
van Ryn, J., Litzenburger, T., & Schurer, J. (2012) · Circulation · doi:10.1161/circ.126.suppl_21.a9928 · Cited by 20
Self-citation
Cited by
Idarucizumab for Dabigatran Reversal
Pollack, C. V., Reilly, P. A., Eikelboom, J., Glund, S., Verhamme, P., Bernstein, R. A., Dubiel, R., Huisman, M. V., Hylek, E. M., Kamphuisen, P. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1502000 · Cited by 1,552
Self-citationIdarucizumab for Dabigatran Reversal — Full Cohort Analysis
Pollack, C. V., Reilly, P. A., van Ryn, J., Eikelboom, J. W., Glund, S., Bernstein, R. A., Dubiel, R., Huisman, M. V., Hylek, E. M., Kam, C.-W., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707278 · Cited by 1,154
Self-citationFrontera, J. A., Lewin III, J. J., Rabinstein, A. A., Aisiku, I. P., Alexandrov, A. W., Cook, A. M., del Zoppo, G. J., Kumar, M. A., Peerschke, E. I. B., Stiefel, M. F., et al. (2016) · Neurocritical Care · doi:10.1007/s12028-015-0222-x · Cited by 706
Andrade, J. G., Aguilar, M., Atzema, C., Bell, A., Cairns, J. A., Cheung, C. C., Cox, J. L., Dorian, P., Gladstone, D. J., Healey, J. S., et al. (2020) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2020.09.001 · Cited by 562
Glund, S., Stangier, J., Schmohl, M., Gansser, D., Norris, S., van Ryn, J., Lang, B., Ramael, S., Moschetti, V., Gruenenfelder, F., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60732-2 · Cited by 319
Self-citation
Metadata
- Authors
- Moschetti, V., Norris, S., Stangier, J., Schmohl, M., Ryn, J. V., Lang, B., Ramael, S., Reilly, P., & Glund, S.
- Venue
- Thrombosis and Haemostasis
- Publisher
- Georg Thieme Verlag KG
- Published
- 2015-09
- Volume
- 113
- Issue
- 05
- Pages
- 943-951
- ISSN
- 0340-6245 (ISSN-L)
- 2567-689X
- OpenAlex
- W2015751459
- Cited by
- 246
- References
- 18
- FWCI
- 39.48
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.